Clinical trial NCT01297959 - References

Infections — Study to Evaluate Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery

Citation(s)

•   Deane J, Simenauer A, Denys GA, O'Hanley P, Stephens JT, Sahm DF
  In vitro activity of E-101, a rapidly bactericidal myeloperoxidase (MPO)-based agent, against key bacterial pathogens. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy
•   Denys GA, Allen RC, O'Hanley P, Stephens JT
  E-101 solution, a first in class topical anti- infective, shows fungicidal activity in vitro against Candida species. 11th ASM Conference on Candida and Candidiasis March 29-April 2, 2012 San Francisco, CA.
•   Denys GA, Shah D, Deane D, Sahm DF, O'Hanley P, Stephens JT
  Antimicrobial susceptibility of E-101 Solution against target aerobic pathogens: A 5-year longititudional study. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Se
•   Denys GA, Shah D, Sahm DF, Allen RC, O'Hanley P
  Stephens JT. In vitro activity of C- 101 solution, a new eosinophil peroxidase (EPO) containing enzyme system, against Gram- negative and Gram-positive pathogens. 52nd Interscience Conference on Antimicrobi
•   Denys, G
  A., O'Hanley P, Stephens, JT. E-101 Solution demonstrates antiviral properties against Herpes Simplex Virus, Human Immunodeficiency Virus, and Human Influenza A/H1N1 Virus. American Society for Microbiology, 110th General meeting, San Diego, CA (
•   Denys, GA, C Schneider, P O'Hanley, JT Stephens, Jr
  , K Babcock. Use of Affinity Biosensor's LifeScale resonant mass measurement to assess antimicrobial activity of E-101 solution, a novel haloperoxidase-based topical antimicrobial agent. American Society
•   Denys, GA, Goheen MP, Allen RC, O'Hanley P, Stephens JT
  Effect of E-101 Solution and its oxidative products on microbial ultrastucture changes associated with microbicidal action. 21st ECCMID/27th ICC, Milan, Italy, May 2011.
•   Denys, GA, KM Koch, RC Allen, P O'Hanley, JT Stephens, Jr
  Superiority of E- 101 solution, a haloperoxidase-containing enzyme product, to sodium oxychlorosene as an antiseptic agent in the presence of serum and whole blood. American Society for Microbiolo
•   Denys, GA, MP Goheen, RC Allen, P O'Hanley, JT Stephens Jr
  Antifungal activity of two potent topical haloperoxidase-based formulations (EPO-based C-101 and MPO-based E- 101) against Candida albicans. American Society for Microbiology, 114th General Meeti
•   O'Hanley P, O'Hanley K, Beausoleil C, Stephens JT
  E-101 Solution (E-101), a Myeloperoxidase (MPO) Antiseptic for Prevention of Surgical Site Infections (SSI): Phase 1 Sensitization and Microbial Reduction in Healthy Adult Volunteers. Program and Abstract
•   O'Hanley, P, Beausoleil C, O'Hanley K, Stephens, JT
  E-101 Solution, a novel antiseptic intended for direct application within a surgical wound to prevent surgical site infection: Blinded, controlled Phase 1 skin irritation study in healthy volunteers. An
•   O'Hanley, P, Pete M, O'Hanley K, Sabo L, Allen R, Stephens JT
  Antibody Responses Not Likely to Affect Efficacy and Safety of E-101 Solution, a Novel Myeloperoxidase (MPO)-based Topical Antiseptic for Prevention of Incisional Infections. Annual Surgical S
•   Pillar C, Denys GA, O'Hanley P, Stephens JT, Sahm D
  E-101, a novel in class topical anti-infective, maintains a high degree of potency in vitro against problematic resistant clinical pathogens (ESKAPE pathogens). 21st ECCMID/27th ICC, Milan, Italy, May 2
•   Pillar, C, Denys GA, O'Hanley P, Stephens JT, Sahm D
  E-101, a novel in class topical anti-infective, has potent activity against clinical isolates of important pathogens in Europe collected from 2008-2010. 21st ECCMID/27th ICC, Milan, Italy, May 2011.

Phase 3 Study of Efficacy and Safety of Topical E-101 Solution to Prevent Incisional Infections Among Colorectal Surgery Patients (Triple IN Study --Inhibition of Incisional Infections)

Details for clinical trial NCT01297959